A Simple Key For ABBV-744 BRD4 inhibition in cancer cell lines Unveiled
In Section C, individuals will acquire ABBV-744 and oral navitoclax. In Phase D, participants will get ABBV-744 and ruxolitinib. Contributors will obtain treatment right up until condition progression or the participants are not able to tolerate the study drugs.Total, our present work highlights the potential utilization of ARV-825 in combination w